<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613300</url>
  </required_header>
  <id_info>
    <org_study_id>GELTAMO-O-CRT-2011</org_study_id>
    <secondary_id>2011-004729-29</secondary_id>
    <nct_id>NCT01613300</nct_id>
  </id_info>
  <brief_title>Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients</brief_title>
  <official_title>Ofatumumab as Part of the Reduced Intensity Conditioning Regimen (RIC) for Patients With High Risk B Non Hodgkin's Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is rate of acute graft-versus-host disease II-IV measured at day&#xD;
      +365according to conventional criteria (Przepiorka et al. 1995) in patients with high risk&#xD;
      non-Hodgkin lymphoma B subjects with Allogeneic Stem Cell Transplant&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In addition to above:&#xD;
&#xD;
        -  Rate of progression-free survival (PFS) at 12, 24, 36 and 60 months post-transplant&#xD;
           defined as the time between the infusion of progenitors and the disease progression or&#xD;
           death. Patients alive or in complete remission will be censored at the time of last&#xD;
           follow up&#xD;
&#xD;
        -  Transplant-related mortality (TRM) at 12, 24, 36 and 60 months after transplantation,&#xD;
           defined as any death not caused directly by lymphoma (any death caused by complications&#xD;
           related to transplantation).&#xD;
&#xD;
        -  Overall survival (OS) defined as the time between infusion of progenitors and the&#xD;
           patient's death from any cause. Alive Patients will be censored at the time of last&#xD;
           follow-up&#xD;
&#xD;
        -  Incidence of chronic graft versus host disease (GVHD) wide at 1 and 5 years according to&#xD;
           conventional criteria (Atkinson et al. 1989) and Filipovich et al. (BBMT, 2005).&#xD;
&#xD;
        -  Rate of event-free survival (DFS) defined as time interval between diagnosis of lymphoma&#xD;
           and lymphoma progression or relapse or death if the above does not occur.&#xD;
&#xD;
        -  Successful graft implantation: is defined as:&#xD;
&#xD;
             1. º: three consecutive days with absolute neutrophil count greater than 0.5 * 109 / L&#xD;
&#xD;
             2. ° thrombocythemia exceeds 20 * 109 / L.&#xD;
&#xD;
        -  Reconstitution of the immune system: lymphocyte count populations CD20, CD3, CD4 and CD8&#xD;
           and immunoglobulinemia serum (days +100, 180, 360, 18 months and 24 months).&#xD;
&#xD;
        -  intercurrent infections. All sorts of infections (viral, fungal and bacterial)will be&#xD;
           recorded&#xD;
&#xD;
        -  Safety assessment by the standards of Common Terminology Criteria for adverse events v.&#xD;
           4.0&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2012</start_date>
  <completion_date type="Actual">June 2020</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of acute grade II-IV graft-versus-host disease at 1 year</measure>
    <time_frame>5 years follow-up</time_frame>
    <description>According to conventional criteria. This endpoint will be descriptively reported. Confidence intervals (95% bounds) will be provided. The rate will be analyzed in all patients enrolled at the clinical trial and that no major violation has been produced.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To analyze the complete response rate after treatment. Further secondary outcomes as described in study summary</measure>
    <time_frame>5 years follow up</time_frame>
    <description>To analyze the complete response rate after treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>B-Cell Lymphomas</condition>
  <arm_group>
    <arm_group_label>Ofatumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ofatumumab as part of the reduced intensity conditioning regimen (RIC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofatumumab</intervention_name>
    <description>Ofatumumab as part of the reduced intensity conditioning regimen (RIC)</description>
    <arm_group_label>Ofatumumab</arm_group_label>
    <other_name>ARZERRA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who have given their informed consent before any study-specific procedures&#xD;
&#xD;
          2. Histopathological diagnostic of NHL cell B CD 20 + B of different histologic subtypes:&#xD;
&#xD;
          3. High risk CD +20 Lymphoma having at least one of the following characteristics:&#xD;
&#xD;
               -  Less than a partial remission after two courses of treatment&#xD;
&#xD;
               -  Relapse after autologous peripheral blood stem cell (PBSCT)&#xD;
&#xD;
               -  Evidence of measurable disease (With CT and PET or PET / CT) three months after&#xD;
                  PBSCT&#xD;
&#xD;
               -  Hematopoietic precursors improper count in patients with relapsed or partial&#xD;
                  remission after two treatment lines that prevent the realization of a PBSCT.&#xD;
&#xD;
               -  Patients after first relapse in RP after two lines of treatment in whom the&#xD;
                  probability of freedom from progression per year is very low due to risk factors&#xD;
                  such as: first CR less than 12 months after PBSCT low SLP, etc..&#xD;
&#xD;
          4. Age between 18 and 65 years&#xD;
&#xD;
          5. ECOG between 0 to 1 (Appendix III).&#xD;
&#xD;
          6. Subjects who are HBgAG negative, anti-HBc positive and HBV DNA negative may be include&#xD;
             in the study but must undergo HBV DNA monitoring&#xD;
&#xD;
          7. Adequate lung Function&#xD;
&#xD;
          8. Cardiac ejection greater than 40% as measured by scintigraphy or echocardiography.&#xD;
&#xD;
          9. Adequate renal and hepatic function defined by the following biochemical parameters&#xD;
&#xD;
         10. The disease status prior to transplantation had to be in place in accordance with the&#xD;
             criteria of Revised Response Criteria for Malignant Lymphoma, Cheson 2007. CT and PET&#xD;
             or PET / CT.&#xD;
&#xD;
         11. Availability of a histocompatible donor (9 to 10/10 loci) family or unrelated&#xD;
&#xD;
         12. Adults with ability to procreate must commit to use an effective method of birth&#xD;
             control during the study treatment and at least 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Refractory disease at the time of transplantation&#xD;
&#xD;
          2. Progressive disease at the time of transplantation.&#xD;
&#xD;
          3. ECOG≤2&#xD;
&#xD;
          4. Lymphoma associated with infection with human immunodeficiency virus (HIV).&#xD;
&#xD;
          5. Test positive for HIV.&#xD;
&#xD;
          6. Presence of anti-murine antibodies (HAMA) or (HACA).&#xD;
&#xD;
          7. Treatment with any marketed or experimental drug administered not in a period between&#xD;
             5 terminal half-lives of clearance of therapy or 4 weeks before enrollment&#xD;
&#xD;
          8. Participation in another interventional clinical trial.&#xD;
&#xD;
          9. Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months&#xD;
             prior to start of therapy. This is generally required and may be excluded as&#xD;
             applicable.&#xD;
&#xD;
         10. Hepatitis B positive serology&#xD;
&#xD;
         11. Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg.&#xD;
&#xD;
         12. Positive serology for hepatitis C (HC) defined as a positive test for HCAb.&#xD;
&#xD;
         13. Active liver or biliary disease (with exception of Gilbert's disease, cholelithiasis,&#xD;
             metastases).&#xD;
&#xD;
         14. Other past or current malignancy.&#xD;
&#xD;
         15. Chronic infectious disease that requires ongoing treatment with systemic antibiotics,&#xD;
             antifungal or antiviral drugs&#xD;
&#xD;
         16. History of cerebrovascular disease active in the last 6 months or event with&#xD;
             significant symptoms or sequelae.&#xD;
&#xD;
         17. Clinically significant heart disease, such as unstable angina, acute myocardial&#xD;
             infarction in the six months prior to inclusion, congestive heart failure (grades&#xD;
             III-IV NYHA) and arrhythmia unless it is controlled by treatment, except for premature&#xD;
             or disorders Mild driving.&#xD;
&#xD;
         18. Concurrent medical disorder, uncontrolled and important, such as kidney disease,&#xD;
             liver, digestive, endocrine, pulmonary, neurological, brain, psychiatric, or which in&#xD;
             the opinion of the investigator may represent a risk to the patient&#xD;
&#xD;
         19. Pregnancy or breastfeeding&#xD;
&#xD;
         20. Women of childbearing potential, including those whose last menstrual period was one&#xD;
             year prior to screening.&#xD;
&#xD;
         21. Men unable or unwilling to use contraception&#xD;
&#xD;
         22. Patients with hypersensitivity to fludarabine, melphalan, thiotepa, tacrolimus,&#xD;
             sirolimus and / or any excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Dolores Caballero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico de Salamanca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. 12 de Octubre,</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Gregorio Marañón,</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Morales Meseguer.</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Clinico de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 5, 2012</study_first_submitted>
  <study_first_submitted_qc>June 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hodgkin</keyword>
  <keyword>disease</keyword>
  <keyword>ofatumumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofatumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

